SENORES

Senores Pharmaceuticals Share Price

₹504.95 -55.7 (-9.93%)

27 Jan, 2025 14:59

SIP TrendupStart SIP in SENORES

Start SIP

Performance

  • Low
  • ₹493
  • High
  • ₹550
  • 52 Week Low
  • ₹435
  • 52 Week High
  • ₹610
  • Open Price₹550
  • Previous Close₹561
  • Volume1,593,600

Investment Returns

  • Over 1 Month + 29.17%
  • Over 3 Month + 29.17%
  • Over 6 Month + 29.17%
  • Over 1 Year + 29.17%
SIP Lightning

Smart Investing Starts Here Start SIP with Senores Pharmaceuticals for Steady Growth!

Invest Now

Senores Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 2,326
  • P/B Ratio
  • 7.6
  • Average True Range
  • 36.33
  • EPS
  • 6.84
  • Dividend Yield
  • 0
  • MACD Signal
  • -
  • RSI
  • 53.03
  • MFI
  • 75.17

Senores Pharmaceuticals Financials

Senores Pharmaceuticals Technicals

EMA & SMA

Current Price
₹504.95
-55.7 (-9.93%)
pointer
  • stock-down_img
  • Bearish Moving Average 7
  • stock-up_img
  • Bullish Moving Average 0
  • 20 Day
  • ₹529.90
  • 50 Day
  • -
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

564.67 Pivot Speed
  • R3 632.33
  • R2 611.12
  • R1 585.88
  • S1 539.43
  • S2 518.22
  • S3 492.98

What's your outlook on Senores Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

N/A

Group Rank

Senores Pharmaceuticals develops and manufactures niche, complex, and specialty pharmaceutical products adhering to international quality standards. With a global focus, the company is committed to innovation, affordable healthcare, and meeting the evolving demands of the healthcare industry.

Senores Pharmaceuticals Ltd has an operating revenue of Rs. 431.58 Cr. on a trailing 12-month basis. An annual revenue growth of 457% is outstanding, Pre-tax margin of 12% is healthy, ROE of 15% is good. The company has a debt to equity of 65%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 6% and 6% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 29 which is a POOR score indicating inconsistency in earnings, a RS Rating of 50 which is POOR indicating the underperformance as compared to other stocks, Group Rank of 34 indicates it belongs to a strong industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Senores Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-01-23 Quarterly Results & Others To consider other business matters.

Senores Pharmaceuticals F&O

Senores Pharmaceuticals Shareholding Pattern

45.76%
4.99%
3.96%
4.25%
0.01%
28.71%
12.32%

About Senores Pharmaceuticals

  • NSE Symbol
  • SENORES
  • BSE Symbol
  • 544319
  • Managing Director
  • Mr. Swapnil Jatinbhai Shah
  • ISIN
  • INE0RB801010

Similar Stocks to Senores Pharmaceuticals

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals share price is ₹504 As on 27 January, 2025 | 14:45

The Market Cap of Senores Pharmaceuticals is ₹2325.5 Cr As on 27 January, 2025 | 14:45

The P/E ratio of Senores Pharmaceuticals is As on 27 January, 2025 | 14:45

The PB ratio of Senores Pharmaceuticals is 7.6 As on 27 January, 2025 | 14:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23